1상모집 중

A Study of LY4170156 in Participants With Selected Advanced Solid Tumors

연구 개요

The purpose of this study is to find out whether the study drug, LY4170156, is safe, tolerable and effective in participants with advanced solid tumors. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-expansion). The study will last up to approximately 4 years.

스폰서: 리드: 일라이 릴리
적응증: Ovarian Neoplasms, Endometrial Neoplasms, Uterine Cervical Neoplasms, Carcinoma, Non-Small-Cell Lung, Triple Negative Breast Neoplasms, Pancreatic Neoplasm, Colorectal Neoplasms
중재: LY4170156, bevacizumab, carboplatin, Itraconazole, pembrolizumab
목표 등록: 495명
시작일: 2024-05-20
완료(예정): 2027-04-01
등록번호: NCT06400472 · ClinicalTrials.gov ↗

BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.